Related Experiment Video

Updated: Sep 23, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Effects of ketanserin administration on lipid metabolism and platelet aggregation in hypertensive patients

C Loschiavo1, E Valvo, V Bedogna

  • 1Divisione Clinicizzata di Nefrologia, Istituti Ospitalieri, Verona, Italy.

International Journal of Clinical Pharmacology, Therapy, and Toxicology
|November 1, 1990
PubMed

Insights

Ketanserin effectively lowers blood pressure and improves lipid profiles in hypertensive patients. The drug also reduces platelet aggregation, suggesting it may help control key cardiovascular risk factors.

Area of Science:

  • Cardiovascular Pharmacology
  • Hypertension Management
  • Lipid Metabolism

Background:

  • Systemic hypertension's atherosclerotic complications are not fully prevented by blood pressure reduction alone.
  • Platelet hyperaggregation and dyslipidemia are significant risk factors in hypertensive individuals.

Purpose of the Study:

  • To evaluate the effects of ketanserin on blood pressure, serum lipids, and platelet aggregation in patients with essential hypertension.

Main Methods:

  • An 8-week treatment study involving 10 patients with essential hypertension.
  • Assessment of blood pressure, serum lipid parameters (cholesterol, triglycerides, LDL, HDL-C, apolipoprotein A1 and B), and platelet aggregation induced by collagen, ADP, and arachidonic acid.

Main Results:

  • Ketanserin lowered blood pressure in all patients, with 6 becoming normotensive.
  • Significant reductions were observed in cholesterol, triglycerides, and apolipoprotein B levels.
  • Significant increases in HDL-C and apolipoprotein A1 were noted.
  • Platelet aggregation induced by collagen and arachidonic acid was significantly reduced.

Conclusions:

  • Ketanserin effectively reduces blood pressure, normalizes serum lipid patterns, and improves platelet aggregation.
  • The drug's mechanism involves alpha-1 adrenoceptor antagonism and inhibition of phosphodiesterase.
  • Ketanserin may be beneficial in managing major cardiovascular risk factors.

More Related Videos

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...